FY2027 Earnings Estimate for IDYA Issued By Leerink Partnrs

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) - Research analysts at Leerink Partnrs increased their FY2027 earnings per share estimates for shares of IDEAYA Biosciences in a research report issued on Monday, October 20th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($4.00) for the year, up from their prior estimate of ($4.04). The consensus estimate for IDEAYA Biosciences' current full-year earnings is ($3.07) per share.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million during the quarter, compared to analyst estimates of $3.48 million. The firm's revenue was up NaN% on a year-over-year basis. During the same period in the previous year, the business earned ($0.68) earnings per share.

Several other research firms have also issued reports on IDYA. Wells Fargo & Company began coverage on IDEAYA Biosciences in a research note on Thursday, June 26th. They set an "overweight" rating and a $44.00 target price on the stock. Royal Bank Of Canada raised their price objective on shares of IDEAYA Biosciences from $38.00 to $41.00 and gave the company an "outperform" rating in a research note on Tuesday. TD Cowen initiated coverage on shares of IDEAYA Biosciences in a report on Tuesday, July 22nd. They set a "buy" rating on the stock. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 9th. Finally, Wall Street Zen lowered IDEAYA Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, October 11th. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $44.19.

IDEAYA Biosciences Stock Down 1.9%

NASDAQ:IDYA opened at $28.64 on Thursday. IDEAYA Biosciences has a 52 week low of $13.45 and a 52 week high of $32.67. The stock's fifty day moving average is $26.02 and its two-hundred day moving average is $22.45. The stock has a market capitalization of $2.51 billion, a price-to-earnings ratio of -7.56 and a beta of 0.14.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its stake in shares of IDEAYA Biosciences by 180.2% in the first quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after buying an additional 1,546 shares in the last quarter. CWM LLC boosted its stake in shares of IDEAYA Biosciences by 325.7% in the first quarter. CWM LLC now owns 2,371 shares of the company's stock valued at $39,000 after buying an additional 1,814 shares in the last quarter. Signaturefd LLC raised its holdings in IDEAYA Biosciences by 374.8% during the first quarter. Signaturefd LLC now owns 2,877 shares of the company's stock worth $47,000 after purchasing an additional 2,271 shares during the last quarter. Elevation Point Wealth Partners LLC acquired a new position in IDEAYA Biosciences in the second quarter valued at $61,000. Finally, Daiwa Securities Group Inc. increased its stake in IDEAYA Biosciences by 16.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company's stock valued at $66,000 after purchasing an additional 436 shares during the last quarter. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.